Physician profile

Daniel L Wooster

Family Medicine · Tulsa, OK

NPI 1518960756

$2,198.77

in general payments reported to CMS, 2019-2025

34 companies · $22.72 in 2025

The $22.72 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,098.80

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $332.72 2020-2024 Ubrelvy, Qulipta
Abbott Laboratories $202.79 2022-2025 Freestyle Libre 3
Pfizer INC. $186.14 2019-2024
Glaxosmithkline, LLC. $180.40 2019-2024 Trelegy Ellipta, Shingrix, Arexvy
Amgen INC. $135.22 2019-2023 Evenity, Prolia, Repatha
Novo Nordisk INC $119.36 2019-2023 Rybelsus, Ozempic
Lilly USA, LLC $114.02 2019-2023 Mounjaro
Bayer Healthcare Pharmaceuticals INC. $112.74 2022-2024
Boehringer Ingelheim Pharmaceuticals, INC. $63.09 2019-2023 Jardiance
Otsuka America Pharmaceutical, INC. $59.73 2023 Rexulti
Janssen Pharmaceuticals, INC $53.64 2021-2022
Biohaven Pharmaceuticals, INC. $43.75 2021
Nevro Corp. $43.04 2021
Nobel Biocare USA $42.80 2020
Astrazeneca Pharmaceuticals LP $41.61 2019-2023 Farxiga
Show all 34 companies
CompanyGeneral paymentsYearsTop products
Dexcom, INC. $40.63 2024 Dexcom G6 Transmitter
Takeda Pharmaceuticals U.S.A., INC. $40.25 2021-2022
Alk-Abello, INC $40.06 2019-2023 Odactra, Grastek, Ragwitek
Astellas Pharma US INC $40.05 2021-2023 Myrbetriq, Veozah
Merck Sharp & Dohme LLC $29.26 2021-2023 Belsomra
Sumitomo Pharma America, INC. $29.24 2024 Gemtesa
Exact Sciences Corporation $28.98 2023-2024 Cologuard Collection Kit
Kowa Pharmaceuticals America, INC. $27.55 2020-2022
Alkermes, INC. $22.79 2021
Eisai INC. $19.93 2024
Esperion Therapeutics, INC. $19.54 2021
Amarin Pharma, INC. $18.91 2021
Biohaven Pharmaceutical Holding Company LTD. $18.33 2022
Allergan, INC. $17.82 2019
Idorsia Pharmaceuticals US INC $16.99 2024 Quviviq
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $16.84 2024 Xifaxan
Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $14.66 2024 Caplyta
Althera Pharmaceuticals LLC $13.35 2021
Bardy Diagnostics, INC. $12.54 2021

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Daniel L Wooster

$2,198.77

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $22.72 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).

https://glasscript.com/doctor/204989/daniel-l-wooster

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.